Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DM2C7U0)

Drug Name
1-(4-Bromobenzyl)-1H-imidazole Drug Info
Synonyms
1-(4-bromobenzyl)-1H-imidazole; 72459-46-2; 1-(4-bromobenzyl)imidazole; 1H-Imidazole, 1-[(4-bromophenyl)methyl]-; CHEMBL211207; 1-[(4-bromophenyl)methyl]imidazole; 1H-Imidazole,1-[(4-bromophenyl)methyl]-; [(4-bromophenyl)methyl]imidazole; AC1MGP7Q; SCHEMBL707075; 1-(4Bromobenzyl)-1H-imidazole; KS-00000LSK; CTK5D6137; DTXSID20388130; MZJSYLIOMLCYIS-UHFFFAOYSA-N; MolPort-000-143-261; 1-(4bromo-benzyl)-1H-imidazole; HMS1603K13; CS-D0078; ZINC4810192; STK951803; ANW-63041; CB-660; SBB098736; BDBM50188088; AKOS002272497; RP05746
Indication
Disease Entry ICD 11 Status REF
Discovery agent N.A. Investigative [1]
Cross-matching ID
PubChem CID
2989557
CAS Number
CAS 72459-46-2
TTD Drug ID
DM2C7U0

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Approved Drug(s)
Investigative Drug(s)
Clinical Trial Drug(s)
Download the Complete Related Drug List
Drug(s) Targeting Steroid 11-beta-hydroxylase (CYP11B1)
Drug Name Drug ID Indication ICD 11 Highest Status REF
FADROZOLE DM3C5GZ Breast cancer 2C60-2C65 Approved [2]
Osilodrostat DMIJC9X Cushing disease 5A70 Approved [3]
Metyrapone DMI7FVQ Cushing disease 5A70 Approved [4]
4'-(Pyridin-4-ylmethyl)biphenyl-3,4-diol DM6Z5EK Discovery agent N.A. Investigative [5]
4-Indan-(1Z)-ylidenemethyl-pyridine DM25DR7 Discovery agent N.A. Investigative [6]
4-[(4'-Hydroxybiphenyl-4-yl)methyl]pyridine DMIEMWA Discovery agent N.A. Investigative [5]
4-[5-Fluoro-indan-(1E)-ylidenemethyl]-pyridine DMY08FE Discovery agent N.A. Investigative [6]
5-[5-Fluoro-indan-(1E)-ylidenemethyl]-pyrimidine DM2RIHT Discovery agent N.A. Investigative [6]
4-((1H-imidazol-1-yl)methyl)benzonitrile DMFUBRC Discovery agent N.A. Investigative [2]
4-[5-Fluoro-indan-(1Z)-ylidenemethyl]-pyridine DMHDZUO Discovery agent N.A. Investigative [6]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Targeting Steroid 17-alpha-monooxygenase (S17AH)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Abiraterone acetate DMANBZI Prostate cancer 2C82.0 Approved [7]
ABIRATERONE DM8V75C Prostate cancer 2C82.0 Approved [8]
TAK-700 DM2H8FZ Prostate cancer 2C82.0 Phase 3 [9]
TAVT-45 DMHBRGT Prostate cancer 2C82.0 Phase 3 [10]
Seviteronel DM9IMEZ Breast cancer 2C60-2C65 Phase 2 [11]
CFG920 DM2BXDU Prostate cancer 2C82.0 Phase 1/2 [12]
DST-2970 DM69ZBU Prostate cancer 2C82.0 Phase 1 [13]
4'-(Pyridin-4-ylmethyl)biphenyl-3,4-diol DM6Z5EK Discovery agent N.A. Investigative [5]
4-Indan-(1Z)-ylidenemethyl-pyridine DM25DR7 Discovery agent N.A. Investigative [6]
4-[(4'-Hydroxybiphenyl-4-yl)methyl]pyridine DMIEMWA Discovery agent N.A. Investigative [5]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas
Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Steroid 11-beta-hydroxylase (CYP11B1) TTIQUX7 C11B1_HUMAN Inhibitor [2]
Steroid 17-alpha-monooxygenase (S17AH) TTRA5BZ CP17A_HUMAN Inhibitor [1]

References

1 Synthesis, biochemical evaluation and rationalisation of the inhibitory activity of a range of 4-substituted phenyl alkyl imidazole-based inhibitor... Bioorg Med Chem Lett. 2006 Sep 15;16(18):4752-6.
2 Synthesis, biological evaluation, and molecular modeling of 1-benzyl-1H-imidazoles as selective inhibitors of aldosterone synthase (CYP11B2). J Med Chem. 2010 Feb 25;53(4):1712-25.
3 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2020
4 Effects of 3-MeSO2-DDE and some CYP inhibitors on glucocorticoid steroidogenesis in the H295R human adrenocortical carcinoma cell line. Toxicol In Vitro. 2002 Apr;16(2):113-21.
5 Replacement of imidazolyl by pyridyl in biphenylmethylenes results in selective CYP17 and dual CYP17/CYP11B1 inhibitors for the treatment of prosta... J Med Chem. 2010 Aug 12;53(15):5749-58.
6 Synthesis and evaluation of (pyridylmethylene)tetrahydronaphthalenes/-indanes and structurally modified derivatives: potent and selective inhibitor... J Med Chem. 2005 Mar 10;48(5):1563-75.
7 CYP17A1 inhibitors in castration-resistant prostate cancer.Steroids.2015 Mar;95:80-7.
8 2011 FDA drug approvals. Nat Rev Drug Discov. 2012 Feb 1;11(2):91-4.
9 Orteronel (TAK-700), a novel non-steroidal 17,20-lyase inhibitor: effects on steroid synthesis in human and monkey adrenal cells and serum steroid levels in cynomolgus monkeys. J Steroid Biochem Mol Biol. 2012 Apr;129(3-5):115-28.
10 Clinical pipeline report, company report or official report of Tavanta Therapeutics
11 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
12 Recent progress in pharmaceutical therapies for castration-resistant prostate cancer. Int J Mol Sci. 2013 Jul 4;14(7):13958-78.
13 Clinical pipeline report, company report or official report of DisperSol Technologies.